MA38559B1 - Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10 - Google Patents
Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10Info
- Publication number
- MA38559B1 MA38559B1 MA38559A MA38559A MA38559B1 MA 38559 B1 MA38559 B1 MA 38559B1 MA 38559 A MA38559 A MA 38559A MA 38559 A MA38559 A MA 38559A MA 38559 B1 MA38559 B1 MA 38559B1
- Authority
- MA
- Morocco
- Prior art keywords
- imidazo
- triazine derivatives
- derivatives used
- pde10 inhibitors
- pde10
- Prior art date
Links
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003918 triazines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818650P | 2013-05-02 | 2013-05-02 | |
| PCT/IB2014/060945 WO2014177977A1 (en) | 2013-05-02 | 2014-04-23 | Imidazo-triazine derivatives as pde10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38559B1 true MA38559B1 (fr) | 2018-04-30 |
Family
ID=50841902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38559A MA38559B1 (fr) | 2013-05-02 | 2014-04-23 | Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10 |
Country Status (33)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111696C2 (uk) * | 2013-05-02 | 2016-05-25 | Пфайзер Інк. | Похідні імідазотриазину як інгібітори рde10 |
| HRP20220144T1 (hr) | 2016-09-09 | 2022-04-15 | Novartis Ag | Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora |
| EP3801499B1 (en) | 2018-06-07 | 2024-02-28 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| BR112022007491A2 (pt) * | 2019-10-21 | 2022-07-12 | Sk Biopharmaceuticals Co Ltd | Medicamento, composição farmacêutica e método para prevenção, alívio ou tratamento de distúrbio cognitivo, e, uso de um composto de imidazopirimidina ou imidazotriazina |
| AU2023214467A1 (en) * | 2022-02-02 | 2024-07-11 | Katholieke Universiteit Leuven | Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead |
| CN117486878A (zh) * | 2023-10-27 | 2024-02-02 | 扬州市普林斯医药科技有限公司 | 一种恩那司他的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| JP2007508241A (ja) | 2003-07-31 | 2007-04-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Ｐｄｅ１０ａ阻害剤を用いる糖尿病および関連障害の処置方法 |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| US20070167426A1 (en) | 2004-06-02 | 2007-07-19 | Schering Corporation | Compounds for the treatment of inflammatory disorders and microbial diseases |
| TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| US20080051419A1 (en) | 2006-07-26 | 2008-02-28 | Pfizer Inc. | Amine derivatives useful as anticancer agents |
| US8207370B2 (en) | 2006-09-26 | 2012-06-26 | Kaneka Corporation | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| EP2203171A2 (en) | 2007-08-21 | 2010-07-07 | Merck Sharp & Dohme Corp. | Cb2 receptor ligands for the treatment of pain |
| DE102007059723A1 (de) | 2007-12-12 | 2009-06-18 | Siemens Medical Instruments Pte. Ltd. | Hörvorrichtung mit Batterieklappenmodul |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| JP2011515401A (ja) | 2008-03-20 | 2011-05-19 | アムジエン・インコーポレーテツド | オーロラキナーゼモジュレーターおよび使用方法 |
| KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| US20130071415A1 (en) | 2010-05-28 | 2013-03-21 | Biocryst Pharmaceuticals, Inc. | Heterocyclic Compounds as Janus Kinase Inhibitors |
| WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| AU2012221828C1 (en) * | 2011-02-23 | 2015-10-01 | Pfizer Inc. | Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders |
| UA111696C2 (uk) * | 2013-05-02 | 2016-05-25 | Пфайзер Інк. | Похідні імідазотриазину як інгібітори рde10 |
-
2014
- 2014-04-23 UA UAA201510060A patent/UA111696C2/uk unknown
- 2014-04-23 BR BR112015027760A patent/BR112015027760A8/pt not_active Application Discontinuation
- 2014-04-23 AU AU2014261070A patent/AU2014261070A1/en not_active Abandoned
- 2014-04-23 GE GEAP201413979A patent/GEP201706675B/en unknown
- 2014-04-23 TN TN2015000490A patent/TN2015000490A1/fr unknown
- 2014-04-23 NZ NZ712949A patent/NZ712949A/en not_active IP Right Cessation
- 2014-04-23 JP JP2016511150A patent/JP6263606B2/ja not_active Expired - Fee Related
- 2014-04-23 KR KR1020157034216A patent/KR101770905B1/ko not_active Expired - Fee Related
- 2014-04-23 WO PCT/IB2014/060945 patent/WO2014177977A1/en not_active Ceased
- 2014-04-23 AP AP2015008843A patent/AP2015008843A0/xx unknown
- 2014-04-23 MA MA38559A patent/MA38559B1/fr unknown
- 2014-04-23 EP EP14727054.0A patent/EP2991989B1/en active Active
- 2014-04-23 CN CN201480024798.1A patent/CN105164134B/zh not_active Expired - Fee Related
- 2014-04-23 DK DK14727054.0T patent/DK2991989T3/en active
- 2014-04-23 CA CA2910759A patent/CA2910759C/en not_active Expired - Fee Related
- 2014-04-23 SG SG11201508201VA patent/SG11201508201VA/en unknown
- 2014-04-23 MX MX2015015163A patent/MX2015015163A/es unknown
- 2014-04-23 ES ES14727054.0T patent/ES2637816T3/es active Active
- 2014-04-23 EA EA201591819A patent/EA027936B1/ru not_active IP Right Cessation
- 2014-04-23 MD MDA20150103A patent/MD20150103A2/ro not_active Application Discontinuation
- 2014-04-23 PE PE2015002303A patent/PE20151940A1/es not_active Application Discontinuation
- 2014-04-29 TW TW103115365A patent/TWI508966B/zh not_active IP Right Cessation
- 2014-04-30 US US14/265,458 patent/US8933224B2/en not_active Expired - Fee Related
- 2014-04-30 UY UY0001035547A patent/UY35547A/es not_active Application Discontinuation
- 2014-04-30 AR ARP140101792A patent/AR096161A1/es unknown
- 2014-11-21 US US14/549,871 patent/US9145427B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 US US14/829,842 patent/US9296761B2/en not_active Expired - Fee Related
- 2015-10-13 CL CL2015003037A patent/CL2015003037A1/es unknown
- 2015-10-19 CU CUP2015000144A patent/CU20150144A7/es unknown
- 2015-10-23 PH PH12015502462A patent/PH12015502462A1/en unknown
- 2015-10-27 CR CR20150591A patent/CR20150591A/es unknown
- 2015-10-30 NI NI201500157A patent/NI201500157A/es unknown
- 2015-11-02 DO DO2015000271A patent/DOP2015000271A/es unknown
- 2015-11-30 EC ECIEPI201550110A patent/ECSP15050110A/es unknown
- 2015-12-01 ZA ZA2015/08968A patent/ZA201508968B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38559B1 (fr) | Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10 | |
| MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
| MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
| MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
| MA35357B1 (fr) | Composes de type anilines | |
| MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
| MA40301A1 (fr) | Composés indolecarboxamides utiles comme inhibiteurs de kinase | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| MA37756B1 (fr) | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane | |
| MA35434B1 (fr) | Amino-quinazolines en tant qu'inhibiteurs de kinase | |
| MX2013006926A (es) | Compuestos y composiciones fotocromicas. | |
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
| MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| MA39317A1 (fr) | Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe | |
| MA38583B1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
| MA40302A1 (fr) | Dérivés de carbazole | |
| MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA38112A1 (fr) | Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa | |
| MA35086B1 (fr) | Compose de triazolopyridine | |
| MA37686B1 (fr) | Composés phénoxyéthyl pipéridine | |
| MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA37719A1 (fr) | Dérivés de pyrimidinone en tant qu'agents anti-malaria | |
| MA35742B1 (fr) | Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques |